Functional mapping of AKT signaling and biomarkers of response from the FAIRLANE Trial of neoadjuvant ipatasertib plus paclitaxel for triple-negative breast cancer. Shi Z, Wulfkuhle J, Nowicka M, Gallagher RI, Saura C, Nuciforo PG, Calvo I, Andersen J, Passos Coelho JL, Gil Gil MJ, Bermejo B, Pratt DA, Ciruelos EM, Villagrasa P, Wongchenko MJ, Petricoin EF, Oliveira M, Isakoff SJ. Clinical Cancer Research. 2022 Mar 1;28(5):993-1003. doi: 10.1158/1078-0432.CCR-21-2498. PMID: 34907082

Histological grade and tumor stage are correlated with expression of receptor activator of nuclear factor Kappa b (Rank) in epithelial ovarian cancers. Gomez R, Tejada M, Rodriguez-Garcia V, Burgues O, Santos-Llamas A, Martinez-Massa A, Marin-Montes A, Tarin J, Cano A. International Journal of Molecular Sciences. 2022 Feb 3;23(3):1742. doi: 10.3390/ijms23031742. PMID: 35163671

Immunological landscape of HER-2 positive breast cancer. Moragon S, Hernando C, Martinez-Martinez M, Tapia M, Ortega-Morillo B, Lluch A, Bermejo B, Cejalvo J. Cancers. 2022 Jun 28;14(13):3167. doi: 10.3390/cancers14133167. PMID: 35804943

Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors. Andreu Y, Soto-Rubio A, Ramos-Campos M, Escriche-Saura A, Martinez M, Gavila J. Scientific Reports. 2022 Nov 4;12(1):18673. doi: 10.1038/s41598-022-22971-x. PMID: 36333362

Impact of the COVID-19 pandemic on a cancer fast-track programme. Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Cancer Control. 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. PMID: 36355430

In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: 10.1016/j.esmoop.2022.100411. PMID: 35219243

In the literature: November 2022. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2022 Nov 17;7(6):100643. doi: 10.1016/j.esmoop.2022.100643. PMID: 36403559

Is axillary assessment of ductal carcinoma in situ of the breast necessary in all cases?. Bellver G, Buch E, Ripoll F, Adrianzen M, Bermejo B, Burgues O, Julve A, Ortega J. Journal of Surgical Research. 2022 Mar;271:145-153. doi: 10.1016/j.jss.2021.10.006. PMID: 34902737

LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Perez-Nunez I, Rozalen C, Palomeque J, Sangrador I, Dalmau M, Comerma L, Hernandez-Prat A, Casadevall D, Menendez S, Liu D, Shen M, Berenguer J, Ruiz I, Pena R, Montanes J, Alba M, Bonnin S, Ponomarenko J, Gomis R, Cejalvo J, Servitja S, Marzese D, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celia-Terrassa T. Nature Cancer. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. PMID: 35301507

MicroRNAs as a clue to overcome breast cancer treatment resistance. Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. Cancer Metastasis Reviews. 2022 Mar;41(1):77-105. doi: 10.1007/s10555-021-09992-0. PMID: 34524579

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. Cancer Communications. 2022 Dec;42(12):1412-1416. doi: 10.1002/cac2.12352. PMID: 35997029

mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. Casadevall D, Hernandez-Prat A, Garc A-Alonso S, Arpi-Llucia O, Menendez S, Qin M, Guardia C, Morancho B, Sanchez-Mart N F, Zazo S, Gavilan E, Sabbaghi M, Eroles P, Cejalvo J, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Molecular Cancer Research. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. PMID: 35348729

Oncolytic viruses: a new immunotherapeutic approach for breast cancer treatment?. Cejalvo JM, Falato C, Villanueva L, Tolosa P, Gonzalez X, Pascal M, Canes J, Gavila J, Manso L, Pascual T, Prat A, Salvador F. Cancer Treatment Reviews. 2022 May;106:102392. doi: 10.1016/j.ctrv.2022.102392. PMID: 35436729

Opioid receptor expression in colorectal cancer: a nested matched case-control study. Belltall A, Mazzinari G, Garrido-Cano I, Giner F, Mari A, Eroles P, Argente-Navarro M, Cata J, Diaz-Cambronero O. Frontiers in Oncology. 2022 Apr 6;12:801714. doi: 10.3389/fonc.2022.801714. PMID: 35463331

Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Geyer C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong A, Arnedos M, Balmana J, Bergh J, Bliss J, Delaloge S, Domchek S, Eisen A, Elsafy F, Fein L, Fielding A, Ford J, Friedman S, Gelmon K, Gianni L, Gnant M, Hollingsworth S, Im S, Jager A, Lakhani S, Janni W, Linderholm B, Liu T, Loman N, Korde L, Loibl S, Lucas P, Marme F, de Duenas E, McConnell R, Phillips K, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer C, Spanic T, Stickeler E, Toi M, Traina T, Viale G, Zoppoli G, Park Y, Yerushalmi R, Yang H, Pang D, Jung K, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke G, Sun Q, Parton M, Colleoni M, Schmidt M, Brufsky A, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt A, Johannsson O. Annals of Oncology. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. PMID: 36228963

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Csoszi T, Anton A, Turner N, Casas MI, Morales S, Alba E, Calvo L, de la Haba-Rodriguez J, Ramos M, Murillo L, Santaballa A, Alonso-Romero JL, Sanchez-Rovira P, Corsaro M, Huang X, Thallinger C, Kahan Z, Gil-Gil M. European Journal of Cancer. 2022 Jun;168:12-24. doi: 10.1016/j.ejca.2022.03.006. PMID: 35429901

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffeis I, Valagussa P, Viale G. Annals of Oncology. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. PMID: 35182721

Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. Cortes J, Rugo H, Cescon D, Im S, Yusof M, Gallardo C, Lipatov O, Barrios C, Perez-Garcia J, Iwata H, Masuda N, Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P. New England Journal of Medicine. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. PMID: 35857659

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Mouron S, Bueno MJ, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, Gil-Gil M, Martinez-Janez N, Apala JV, Caleiras E, Ximénez-Embún P, Muñoz J, Gonzalez-Cortijo L, Murillo R, Sánchez-Bayona R, Cejalvo JM, Gómez-López G, Fustero-Torre C, Sabroso-Lasa S, Malats N, Martinez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M. Nature Communications. 2022 Dec 7;13(1):7529. doi: 10.1038/s41467-022-35065-z. PMID: 36477027

Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. Villacampa G, Falato C, Pare L, Hernando C, Arumi M, Saura C, Gomez G, Munoz M, Gil-Gil M, Izarzugaza Y, Ferrer N, Najera-Zuloaga J, Montano A, Ciruelos E, Gonzalez-Santiago S, Villagrasa P, Gavila J, Prat A, Pascual T. European Journal of Cancer. 2022 Oct;174:232-242. doi: 10.1016/j.ejca.2022.07.028. PMID: 36067616

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). Albanell J, Martinez M, Ramos M, O’Connor M, de la Cruz-Merino L, Santaballa A, Martinez-Janez N, Moreno F, Fernandez I, Alarcon J, Virizuela J, de la Haba-Rodriguez J, Sanchez-Rovira P, Gonzalez-Cortijo L, Margeli M, Sanchez-Munoz A, Anton A, Casas M, Bezares S, Rojo F. European Journal of Cancer. 2022 Jan;161:26-37. doi: 10.1016/j.ejca.2021.11.010. PMID: 34902765

Referral criteria to clinical genetics from primary care: consensus document. Ejarque Domenech I, Marin Reina P, Garcia-Minaur Rica S, Chirivella Gonzalez I, Martinez Martinez M, Garcia Rodriguez A, Alvarez de Andres S, Telleria Orriols J. Atencion Primaria. 2022 Nov 11;54(12):102501. doi: 10.1016/j.aprim.2022.102501. PMID: 36375295

Relationship between nutritional treatment compliance and nutritional status improvements in patients with gastrointestinal impairment taking an oral peptide-based supplement. Lopez-Medina J, Lopez-Rodriguez C, Estornell-Gualde M, Rey-Fernandez L, Gomez-Senent S, Joaquin-Ortiz C, Fernandez-Soto M, Hurtado-Garcia R, Martin-Martin M, Barrera-Martin A, Vitales-Farrero M, Martinez-Ortega A, Blanca-Martinez-Barbeito M, Vazquez-Vizcaino B, Tasende-Fernandez C, Penacho-Lazaro M, Jorda-Sorolla E, Sanchez-Sanchez R, Diaz-Gomez L, Baos-Fernandez S, Guzman-Rolo G, Ballesteros-Pomar M. Nutrition. 2022 Oct;102:111734. doi: 10.1016/j.nut.2022.111734. PMID: 35839658

Role of SALL4 in HER2+breast cancer progression: regulating PI3K/AKT Pathway. Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgues O, Rovira A, Martinez M, Tapia M, Zazo S, Albanell J, Rojo F, Bermejo B, Eroles P. International Journal of Molecular Sciences. 2022 Oct 31;23(21):13292. doi: 10.3390/ijms232113292. PMID: 36362083

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. Salvador Bofill J, Moreno Anton F, Rodriguez Sanchez CA, Galve Calvo E, Hernando Melia C, Ciruelos Gil EM, Vidal M, Jimenez-Rodriguez B, De la Cruz Merino L, Martinez Janez N, Villanueva Vazquez R, de Toro Salas R, Anton Torres A, Alvarez Lopez IM, Gavila Gregori J, Quiroga Garcia V, Vicente Rubio E, De la Haba-Rodriguez J, Gonzalez-Santiago S, Diaz Fernandez N, Barnadas Molins A, Cantos Sanchez de Ibarguen B, Delgado Mingorance JI, Bellet Ezquerra M, de Casa S, Gimeno A, Martin M. Breast. 2022 Sep 28;66:77-84. doi: 10.1016/j.breast.2022.09.006. PMID: 36206609

Solid tumor opioid receptor expression and oncologic outcomes: analysis of the cancer genome atlas and genotype tissue expression Project. Belltall A, Zuniga-Trejos S, Garrido-Cano I, Eroles P, Argente-Navarro M, Buggy D, Diaz-Cambronero O, Mazzinari G. Frontiers in Oncology. 2022 Mar 10;12:801411. doi: 10.3389/fonc.2022.801411. PMID: 35359418

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. Future Oncology. 2022 Oct 6. doi: 10.2217/fon-2022-0660. PMID: 36200668

Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+breast tumors. Rivas EI, Linares J, Zwick M, Gomez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Llado A, Bardia L, Perez-Nunez I, Martinez-Ciarpaglini C, Tarazona N, Sallent-Aragay A, Garrido M, Celia-Terrassa T, Burgues O, Gomis RR, Albanell J, Calon A. Nature Communications. 2022 Sep 9;13(1):5310. doi: 10.1038/s41467-022-32782-3. PMID: 36085201

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Adam-Artigues A, Arenas E, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martinez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martinez D, Rovira A, Burgues O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Science Advances. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. PMID: 35594351

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Valeria Bianchi G, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. Molecular Oncology. 2022 Jun;16(12):2355-2366. doi: 10.1002/1878-0261.13141. PMID: 34816585

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview. Vazquez J, Pinero A, de Castro F, Lluch A, Martin M, Barnadas A, Alba E, Rodriguez-Lescure A, Rojo F, Gimenez J, Sola I, Quintana M, Bonfill X, Urrutia G, Sanchez-Rovira P. Clinical & Translational Oncology. 2022 Sep;24(9):1744-1754. doi: 10.1007/s12094-022-02824-9. PMID: 35414152

Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel. Jimenez N, Reig O, Marin-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, Rodriguez-Vida A, Climent MA, Cros S, Chirivella I, Domenech M, Figols M, Gonzalez-Billalabeitia E, Jimenez Peralta D, Rodriguez-Carunchio L, Garcia-Esteve S, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B. Cancers. 2022 Sep 29;14(19):4757. doi: 10.3390/cancers14194757. PMID: 36230681

Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study. Donat-Vargas C, Guerrero-Zotano A, Lope V, Bermejo B, Casas A, Baena-Canada J, Antolin S, Sanchez-Rovira P, Anton A, Garcia-Saenz J, Ramos M, Munoz M, de Juan A, Sanchez C, Chacon J, Gil-Gil M, Conejero R, Llombart A, Bezares S, de Larrea-Baz N, Perez-Gomez B, Martin M, Pollan M. European Journal of Clinical Nutrition. 2022 Sep;76(9):1343-1346. doi: 10.1038/s41430-022-01101-w. PMID: 35194197

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, Martinez-Saez O, Adamo B, Vidal M, Barnadas E, Fernandez-Martinez A, Gonzalez-Farre B, Sanfeliu E, Cejalvo J, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavila J, Barrios C, Lluch A, Martin M, Locci M, De Placido S, Prat A. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2. PMID: 33397968

Expression of phosphorylated BRD4 is markedly associated with the activation status of the PP2A pathway and shows a strong prognostic value in triple negative breast cancer patients. Sanz-Alvarez M, Cristobal I, Luque M, Santos A, Zazo S, Madoz-Gurpide J, Carames C, Chiang C, Garcia-Foncillas J, Eroles P, Albanell J, Rojo F. Cancers. 2021 Mar 12;13(6):1246. doi: 10.3390/cancers13061246. PMID: 33809005

Fertility and breast cancer: a literature review of counseling, preservation options and outcomes. Moragon S, Di Liello R, Bermejo B, Hernando C, Olcina E, Chirivella I, Lluch A, Cejalvo JM, Martinez MT, Critical Reviews In Oncology/Hematology. 2021 Aug 27;166:103461. doi: 10.1016/j.critrevonc.2021.103461. PMID: 34461268

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. Dent R, Oliveira M, Isakoff S, Im S, Espie M, Blau S, Tan A, Saura C, Wongchenko M, Xu N, Bradley D, Reilly S, Mani A, Kim S, LOTUS Investigators. Breast Cancer Research and Treatment. 2021 Sep;189(2):377-386. doi: 10.1007/s10549-021-06143-5. PMID: 34264439

First nationwide molecular screening program in Spain for patients with advanced breast cancer: results from the AGATA SOLTI-1301 Study. Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodon J, Burgues O, Nuciforo P, Canes J, Pare L, Duenas M, Vidal M, Cejalvo J, Perello A, Llommbard-Cussac A, Dorca J, Montano A, Pascual T, Oliveira M, Ribas G, Rapado I, Prat A, Ciruelos E. Frontiers in Oncology. 2021 Nov 4;11:744112. doi: 10.3389/fonc.2021.744112. PMID: 34804931

Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Munoz M, Bermejo B, Margeli M, Anton A, Casas M, Csoszi T, Murillo L, Morales S, Calvo L, Lang I, Alba E, de la Haba-Rodriguez J, Ramos M, Lopez I, Gal-Yam E, Garcia-Palomo A, Alvarez E, Gonzalez-Santiago S, Rodriguez C, Servitja S, Corsaro M, Rodrigalvarez G, Zielinski C, Martin M. European journal of cancer. 2021 Aug 20;156:70-82. doi: 10.1016/j.ejca.2021.07.004. PMID: 34425406

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Pare L, Pernas S, Munoz M, Oliveira M, Vidal M, Llombart-Cussac A, Cortes J, Galvan P, Bermejo B, Martinez N, Lopez R, Morales S, Garau I, Manso L, Alarcon J, Martinez E, Villagrasa P, Prat A, Nuciforo P. NPJ Precision Oncology. 2021 Mar 19;5(1):23. doi: 10.1038/s41698-021-00163-6. PMID: 33742063

In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: 10.1016/j.esmoop.2021.100116. PMID: 33887688

In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: 10.1016/j.esmoop.2021.100247. PMID: 34411970

In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602

In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: 10.1016/j.esmoop.2021.100186. PMID: 34098228

Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Van Bockstal M, Francois A, Altinay S, Arnould L, Balkenhol M, Broeckx G, Burgues O, Colpaert C, Dedeurwaerdere F, Dessauvagie B, Duwel V, Floris G, Fox S, Gerosa C, Hastir D, Jaffer S, Kurpershoek E, Lacroix-Triki M, Laka A, Lambein K, MacGrogan G, Marchio C, Martinez M, Nofech-Mozes S, Peeters D, Ravarino A, Reisenbichler E, Resetkova E, Sanati S, Schelfhout A, Schelfhout V, Shaaban A, Sinke R, Stanciu-Pop C, van Deurzen C, van de Vijver K, Van Rompuy A, Vincent-Salomon A, Wen H, Wong S, Bouzin C, Galant C. Modern Pathology. 2021 Dec;34(12):2130-2140. doi: 10.1038/s41379-021-00865-z. PMID: 34218258

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/s41416-021-01502-x. PMID: 34493820

Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez R. ACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: 10.1021/acssensors.0c02222. PMID: 33599490

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Pascual T, Oliveira M, Villagrasa P, Ortega V, Pare L, Bermejo B, Morales S, Amillano K, Lopez R, Galvan P, Canes J, Salvador F, Nuciforo P, Rubio IT, Llombart-Cussac A, Di Cosimo S, Baselga J, Harbeck N, Prat A, Cortes J. NPJ Breast Cancer. 2021 Nov 25;7(1):145. doi: 10.1038/s41523-021-00351-4. PMID: 34824288

Oral Selective Estrogen Receptor Degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo J. International Journal of Molecular Sciences. 2021 Jul 22;22(15):7812. doi: 10.3390/ijms22157812. PMID: 34360578

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos E, Munoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csoszi T, Casas M, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Bartlett C, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Saenz J, Chacon J, Swift C, Thallinger C, Gil-Gil M. Annals of oncology : official journal of the European Society for Medical Oncology. 2021 Apr;32(4):488-499. doi: 10.1016/j.annonc.2020.12.013. PMID: 33385521

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial. Perez-Garcia JM, Llombart-Cussac A, Cortes MG, Curigliano G, Lopez-Miranda E, Alonso JL, Bermejo B, Calvo L, Caranana V, de la Cruz Sanchez S, Vazquez RM, Prat A, Borrego MR, Sampayo-Cordero M, Segui-Palmer MA, Soberino J, Malfettone A, Schmid P, Cortes J. European Journal of Cancer. 2021 May;148:382-394. doi: 10.1016/j.ejca.2021.02.028. PMID: 33794440

Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer. Guardia C, Bianchini G, Arpi-LLucia O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero J, Soria-Jimenez L, Sabbaghi M, Pena R, Madoz-Gurpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Clinical Cancer Research. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915. PMID:34385295

Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification: the NEOVATTL study. Vieites B, Lopez-Garcia M, Martin-Salvago M, Ramirez-Tortosa C, Rezola R, Sancho M, Lopez-Vilaro L, Villardell F, Burgues O, Fernandez-Rodriguez B, Alfaro L, Peg V. Clinical & Translational Oncology. 2021 Jul;23(7):1377-1385. doi: 10.1007/s12094-020-02530-4. PMID: 33517542

Prevalence and clinicopathological characteristics of moderate and high-penetrance genes in non-BRCA1/2 breast cancer high-risk Spanish families. Fonfria M, Jimenez I, Tena I, Chirivella I, Richart-Aznar P, Segura A, Sanchez-Heras A, Martinez-Duenas E. Journal of Personalized Medicine. 2021 Jun 12;11(6):548. doi: 10.3390/jpm11060548. PMID: 34204722

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. NPJ Breast Cancer. 2021 Apr 16;7(1):44. doi: 10.1038/s41523-021-00251-7. PMID: 33863913

Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of clipped node improve our results?. Alarcon M, Buch E, Julve A, Hernandorena M, Tajahuerce M, Rodriguez H, Bermejo B, Ramirez J, Burgues O, Diaz S, Alcala G, Ortega J. Surgeon. 2021 Dec;19(6):344-350. doi: 10.1016/j.surge.2021.01.013. PMID: 33663946

SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of patritumab deruxtecan, a her3 directed antibody drug conjugate, in patients with early breast cancer. Pascual T, Oliveira M, Ciruelos E, Ezquerra M, Saura C, Gavila J, Pernas S, Munoz M, Vidal M, Vila M, Cejalvo J, Gonzalez-Farre B, Espinosa-Bravo M, Cruz J, Salvador-Bofill F, Guerra J, Barrera A, de Dios M, Esker S, Fan P, Martinez-Saez O, Villacampa G, Pare L, Ferrero-Cafiero J, Villagrasa P, Prat A. Frontiers in Oncology. 2021 Apr 23;11:638482. doi: 10.3389/fonc.2021.638482. PMID: 33968735

Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in HER2-positive breast cancer. Luque M, Sanz-Alvarez M, Santamaria A, Zazo S, Cristobal I, de la Fuente L, Minguez P, Eroles P, Rovira A, Albanell J, Madoz-Gurpide J, Rojo F. International Journal of Molecular Sciences. 2021 Dec 10;22(24):13297. doi: 10.3390/ijms222413297. PMID: 34948097

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. PMID: 33989988

Trajectories of alcohol consumption during life and the risk of developing breast cancer. Donat-Vargas C, Guerrero-Zotano A, Casas A, Baena-Canada J, Lope V, Antolin S, Garcia-Saenz J, Bermejo B, Munoz M, Ramos M, de Juan A, Sanchez C, Sanchez-Rovira P, Anton A, Brunet J, Gavila J, Salvador J, Arellano E, Bezares S, de Larrea-Baz N, Perez-Gomez B, Martin M, Pollan M. British Journal of Cancer. 2021 Oct;125(8):1168-1176. doi: 10.1038/s41416-021-01492-w. PMID: 34483338

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer. Garrido Cano I, Constancio V, Adam Artigues A, Lameirinhas A, Simon Alonso S, Ortega Morillo B, Martinez Martinez M, Hernando Meliá C, Bermejo De Las Heras B, Lluch Hernández A, Lopes P, Henrique R, Jeronimo C, Cejalvo Andujar J, Eroles Asensio P. International Journal of Molecular Sciences. 2020 Oct 8;21(19):7427. doi: 10.3390/ijms21197427. PMID: 33050096

Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia. Ballester Garcia S, Pineda Merlo B, Rodrigues P, Tormo Martin E, Terol Castera M, Eroles Asensio P. Genes. 2020 Jun 23;11(6):686. doi: 10.3390/genes11060686. PMID: 32585853

Combination of phenotype and polygenic risk score in breast cancer risk evaluation in the Spanish population: a case -control study. Trivino J, Ceba A, Rubio-Solsona E, Serra D, Sanchez-Guiu I, Ribas G, Rosa R, Cabo M, Bernad L, Pita G, Gonzalez-Neira A, Legarda G, Diaz J, García Vigara A, Martinez Aspas A, Escrig M, Bermejo De Las Heras B, Eroles Asensio P, Ibanez J, Salas D, Julve Parreño A, Cano Sanchez A, Lluch Hernández A, Minambres R, Benitez J. BMC Cancer.2020 Nov 10;20(1):1079. doi: 10.1186/s12885-020-07584-9. PMID: 33167914

Differential expression of Receptor Activator of Nuclear Factor Kappa B in healthy endometrium, ovarian endometrioma and endometrioid ovarian cancer. Gregori Romero M, Rodriguez Garcia V, Burgues Gasion O, Martinez Carmona J, Tarin Folgado J, Cano Sanchez A, Gómez Gallego R. American Journal of Obstetrics and Gynecology. 2020 Mar;222(3):279-281. doi: 10.1016/j.ajog.2019.11.1259. PMID: 31765641

FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. Garcia-Recio S, Thennavan A, East M, Parker J, Cejalvo J, Garay J, Hollern D, He X, Mott K, Galvan P, Fan C, Selitsky S, Coffey A, Marron D, Braso-Maristany F, BURGUES GASION O, Albanell J, Rojo F, Lluch Hernández A, Martinez de Duenas E, Rosen J, Johnson G, Carey L, Prat A, Perou C. Journal of Clinical Investigation. 2020 Sep 1;130(9):4871-4887. doi: 10.1172/JCI130323. PMID: 32573490

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Oltra Sanchis S, Cejalvo Andujar J, Tormo Martin E, Albanell M, Ferrer A, Nacher M, Bermejo De Las Heras B, Hernando Meliá C, Chirivella González I, Alonso Yuste E, Burgues Gasion O, Peña Chilet M, Eroles Asensio P, Lluch Hernández A, Ribas Despuig G, Martinez Martinez M. Cancers. 2020 Feb 10;12(2):412. doi: 10.3390/cancers12020412. PMID: 32050699

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortes J, Rexer B, Pare L, Forero A, Wolff A, Morales S, Adamo B, Braso-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galvan P, Pavlick A, Bermejo De Las Heras B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho J, Hilsenbeck S, Oliveira M, Dieci M, Griguolo G, Fasani R, Nuciforo P, Parker J, Conte P, Schiff R, Guarneri V, Osborne C, Rimawi M. Jnci-Journal of the National Cancer Institute. 2020 Jan 1;112(1):46-54. doi: 10.1093/jnci/djz042. PMID: 31037288

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization. Sanchez-Heras A, Castillejo A, Garcia-Diaz J, Robledo M, Teule A, Sanchez R, Zuniga A, Lastra E, Duran M, Llort G, Yague C, Ramon Y Cajal T, Lopez San Martin C, Lopez-Fernandez A, Balmana J, Robles L, Mesa-Latorre J, Chirivella González I, Fonfria M, Perea Ibanez R, Castillejo M, Escandell Gonzalez I, Gomez L, Berbel P, Soto J. Cancers. 2020 Nov 5;12(11):3277. doi: 10.3390/cancers12113277. PMID: 33167498

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Quintela-Fandino M, Holgado E, Manso L, Morales S, Bermejo De Las Heras B, Colomer R, Apala J, Blanco R, Munoz M, Caleiras E, Iranzo V, Martinez M, Dominguez O, Hornedo J, Gonzalez-Cortijo L, Cortes J, Gasol Cudos A, Malon D, Lopez-Alonso A, Moreno-Ortiz M, Mouron S, Manes S. Breast cancer research. 2020 Nov 11;22(1):124. doi: 10.1186/s13058-020-01362-y. PMID: 33176887

In the literature: August 2020. Gambardella V, Cejalvo J, Tarazona N, Cervantes A. ESMO Open. 2020 Aug;5(4):e000909. doi: 10.1136/esmoopen-2020-000909. PMID: 32817070

In the literature: December 2019. Gambardella V, Insa A, Cejalvo J, Cervantes A. ESMO Open. 2020 Jan;5(1):e000642. doi: 10.1136/esmoopen-2019-000642. PMID: 31958287

In the literature: February 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. ESMO Open. 2020 Feb;5(1):e000680. doi: 10.1136/esmoopen-2020-000680. PMID: 32079625

In the literature: June 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. ESMO Open. 2020 Jul;5(4):e000832. doi: 10.1136/esmoopen-2020-000832. PMID: 32641355

KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi’s sarcoma. Medina M, D’Agostino A, Ma Q, Eroles P, Cavallin L, Chiozzini C, Sapochnik D, Cymeryng C, Hyjek E, Cesarman E, Naipauer J, Mesri E, Coso O. PLoS pathogens. 2020 Oct 15;16(10):e1009006. doi: 10.1371/journal.ppat.1009006. PMID: 33057440

MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma. Pattanayak C, Garrido Cano I, Adam Artigues A, Tormo Martin E, Pineda Merlo B, Cabello Navarro P, Alonso Yuste E, Bermejo De Las Heras B, Hernando Meliá C, Martinez Martinez M, Rovira A, Albanell J, Rojo F, Burgues Gasion O, Cejalvo Andujar J, Lluch Hernández A, Eroles Asensio P. Frontiers in Oncology. 2020 Sep 10;10:1661. doi: 10.3389/fonc.2020.01661. PMID: 33014831

Mu Opioid Receptor 1 (MOR-1) Expression in Colorectal Cancer and Oncological Long-Term Outcomes: A Five-Year Retrospective Longitudinal Cohort Study. Diaz-Cambronero O, Mazzinari G, Giner F, Belltall A, Ruiz-Boluda L, Marques-Mari A, Sanchez-Guillen L, Eroles Asensio P, Cata J, Argente-Navarro M. Cancers. 2020 Jan 5;12(1):134. doi: 10.3390/cancers12010134. PMID: 31948099

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Rosello S, Pizzo C, Huerta M, Munoz E, Aliaga R, Vera A, Alfaro-Cervello C, Jorda E, Garces-Albir M, Roda D, Dorcaratto D, Tarazona N, Torondel S, Guijarro J, Sanchiz V, Gambardella V, Fleitas-Kanonnikoff T, Lluch P, Pascual I, Ferrandez A, Sabater L, Cervantes A. ESMO Open. 2020 Nov;5(6):e000929. doi: 10.1136/esmoopen-2020-000929. PMID: 33229503

Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial. Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Pare L, Escriva-de-Romani S, Manso L, Adamo B, Martinez de Duenas E, Cortes J, Vazquez S, Perello A, Garau I, Mele M, Martinez Janez N, Montano A, Bermejo De Las Heras B, Morales S, Echarri M, Vega E, Gonzalez-Farre B, Martinez D, Galvan P, Canes J, Nuciforo P, Gonzalez Farre X, Prat A. Clinical Cancer Research. 2020 Nov 15;26(22):5820-5829. doi: 10.1158/1078-0432.CCR-20-0844. PMID: 32938620

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP). Manso L, Hernando C, Galan M, Oliveira M, Cabrera MA, Bratos R, Rodriguez CA, Ruiz Borrego M, Blanch S, Llombart Cussac A, Delgado Mingorance JI, Alvarez Busto I, Gallegos I, Gonzalez Cortijo L, Morales S, Aguirre E, Hernando BA, Ballesteros A, Ales-Martinez J, Reboredo C, Oltra A, Gonzalez Cao M, Santisteban M, Malon D, Echeverria I, Garcia Garre E, Vega E, Servitja S, Andres R, Robles CE, Lopez R, Galve E, Echarri MJ, Legeren M, Moreno F. Breast. 2020 Dec;54:286-292. doi: 10.1016/j.breast.2020.11.005. PMID: 33242755

Personalized Medicine: Recent Progress in Cancer Therapy. Gambardella V, Tarazona Llavero N, Cejalvo Andujar J, Lombardi P, Huerta Alvaro M, Roselló Keränen S, Fleitas Kanonnikoff T, Roda Perez D, Cervantes Ruiperez A. Cancers. 2020 Apr 19;12(4):1009. doi: 10.3390/cancers12041009. PMID: 32325878

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Garrido-Castro A, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, Gavila J, Serra V, Prat A, Pare L, Celiz P, Villagrasa P, Li Y, Savoie J, Xu Z, Arteaga C, Krop I, Solit D, Mills G, Cantley L, Winer E, Lin N, Rodon J. Breast Cancer Research. 2020 Nov 2;22(1):120. doi: 10.1186/s13058-020-01354-y. PMID: 33138866

Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). Ciruelos E, Montano A, Rodriguez C, Gonzalez-Flores E, Lluch Hernández A, Garrigos L, Quiroga V, Anton A, Malon D, Chacon J, Velasco M, Gonzalez-Cortijo L, Jolis L, Echarri M, Munoz M, Pascual T, Amigo Y, Casas M, Carrasco E, Casas A. European Journal of Cancer Care. 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. PMID: 32578279

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Lluch Hernández A, Barrios C, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano A, Garcia-Saenz J, Torres R, de la Haba J, Garcia-Martinez E, Gomez H, Llombart A, Salvador Bofill J, Baena-Canada J, Barnadas A, Calvo L, Perez-Michel L, Ramos M, Fernandez I, Rodriguez-Lescure A, Cardenas J, Vinholes J, Martinez de Duenas E, Godes M, Segui M, Anton A, Lopez-Alvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero M, Bezares S, Carrasco E, Martin M, Corona J, Jara C, Cardemil B, Toro R, Pimentel C, Hernando B, Vicente E, Zagame L, Gil M, Garcia Estevez L, Rodriguez C, de la Cruz M, Tello J, Campos S, Lomas M, Capdevile D, Campos M, Margeli M, Andres R, Tusquets I, Ballesteros A, Guerrero A, Arguello M, Rodriguez J, Munoz M, Florian J, Azevedo S, Mondragon R, Peralta J, Palomo A, Barajas L, Arcusa A, Carranza H, Garcia C, Umbria C, Ales J, Lopez Vega J, Romeo M, Valero J, Alonso J, Mathias C, Gutierrez F, Adrover E, Nunez P, Mendiola C, Cassinello J, de la Huerta A, Geicam Spanish Breast Canc Grp, CIBOMA Iberoamer Coalition Res Bre, LACOG. Journal of Clinical Oncology. 2020 Jan 20;38(3):203-213. doi: 10.1200/JCO.19.00904. PMID: 31804894

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Braso-Maristany F, Griguolo G, Pascual T, Pare L, Nuciforo P, Llombart-Cussac A, Bermejo De Las Heras B, Oliveira M, Morales S, Martinez N, Vidal M, Adamo B, Martinez O, Pernas S, Lopez R, Munoz M, Chic N, Galvan P, Garau I, Manso L, Alarcon J, Martinez E, Gregorio S, Gomis R, Villagrasa P, Cortes J, Ciruelos E, Prat A. Nature Communications. 2020 Jan 20;11(1):385. doi: 10.1038/s41467-019-14111-3. PMID: 31959756

Polymorphisms in genes involved in T-cell co-stimulation are associated with blood pressure in women. Pineda Merlo B, Pertusa Viñuales C, Panach Gonzalez L, Tarin Folgado J, Cano Sanchez A, García Pérez M. Gene. 2020 Sep 5;754:144838. doi: 10.1016/j.gene.2020.144838. PMID: 32525043

Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. Fernandez de Larrea-Baz N, Perez-Gomez B, Guerrero-Zotano A, Casas A, Bermejo De Las Heras B, Baena-Canada J, Antolin S, Sanchez-Rovira P, Ramos Vazquez M, Garcia-Saenz J, Anton A, Munoz M, de Juan A, Jara C, Chacon J, Arcusa A, Gil-Gil M, Adrover E, Oltra A, Brunet J, Gonzalez S, Bezares S, Lope V, Martin M, Pollan M. Scientific Reports. 2020 May 8;10(1):7741. doi: 10.1038/s41598-020-63637-w. PMID: 32385335

Reply to Y. Usui et al. Lluch Hernández A, Barrios C, Torrecillas L, Martin M. Journal of Clinical Oncology. 2020 Jun 20;38(18):2113-2114. doi: 10.1200/JCO.20.00390. PMID: 32352858

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Prat A, Saura C, Pascual T, Hernando C, Munoz M, Pare L, Farre B, Fernandez P, Galvan P, Chic N, Farre X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montano A, Izarzugaza Y, Llombart-Cussac A, Bratos R, Santiago S, Martinez E, Hoyos S, Rojas B, Virizuela J, Ortega V, Lopez R, Celiz P, Ciruelos E, Villagrasa P, Gavila J. Lancet Oncology. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. PMID: 31838010

SEOM clinical guideline for treatment of kidney cancer (2019). Lazaro M, Valderrama B, Suarez C, De-Velasco G, Beato C, Chirivella González I, Gonzalez-del-Alba A, Lainez N, Mendez-Vidal M, Arranz J. Clinical & Translational Oncology. 2020 Feb;22(2):256-269. doi: 10.1007/s12094-019-02285-7. PMID: 31993962

Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. Lope V, Guerrero-Zotano A, Casas A, Baena-Canada J, Bermejo B, Perez-Gomez B, Criado-Navarro I, Antolin S, Sanchez-Rovira P, Ramos-Vazquez M, Anton A, Castello A, Garcia-Saenz J, Munoz M, de Juan A, Andres R, Llombart-Cussac A, Hernando B, Franquesa R, Caballero R, Priego-Capote F, Martin M, Pollan M. Nutrients. 2020 Oct 14;12(10):3132. doi: 10.3390/nu12103132. PMID: 33066483

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Pascual T, Cejalvo Andujar J, Oliveira M, Vidal M, Vega E, Ganau S, Julve Parreño A, Zamora E, Miranda I, Delgado A, Bermejo De Las Heras B, la Cruz-Merino L, Juan M, Ferrero-Cafiero J, Canes J, Gonzalez X, Villagrasa P, Prat A. Future oncology (London, England). 2020 Aug;16(24):1801-1813. doi: 10.2217/fon-2020-0246. PMID: 32633563

The economic burden of metastatic breast cancer in Spain. Bermejo de las Heras B, Ramon y Cajal J, Galve Calvo E, de la Haba Rodriguez J, Garcia Mata J, Moreno Anton F, Pelaez Fernandez I, Rodriguez Lescure A, Rodriguez Sanchez CA, Ruiz-Borrego M, Remak E, Barra M, Rivero M, Soto Alvarez J. European Journal of Hospital Pharmacy-Science and Practice. 2020 Jan;27(1):19-24. doi: 10.1136/ejhpharm-2017-001453. PMID: 32064084

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. Hruschka N, Kalisz M, Subijana M, Grana-Castro O, Del Cano-Ochoa F, Brunet L, Chernukhin I, Sagrera A, De Reynies A, Kloesch B, Chin S, Burgues Gasion O, Andreu D, Bermejo De Las Heras B, Cejalvo Andujar J, Sutton J, Caldas C, Ramon-Maiques S, Carroll J, Prat A, Real F, Martinelli P. Oncogene. 2020 Aug;39(32):5455-5467. doi: 10.1038/s41388-020-1376-3. PMID: 32587399

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.. Gonzalez-Alonso P, Zazo S, Martin-Aparicio E, Luque M, Chamizo C, Sanz-Alvarez M, Minguez P, Gomez-Lopez G, Cristobal I, Carames C, Garcia-Foncillas J, Eroles Asensio P, Lluch Hernández A, Arpi O, Rovira A, Albanell J, Piersma S, Jimenez C, Madoz-Gurpide J, Rojo F. Cancers. 2020 Apr 29;12(5):1108. doi: 10.3390/cancers12051108. PMID: 32365528

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation. Fernandez-Nogueira P, Mancino M, Fuster G, Lopez-Plana A, Jauregui P, Almendro V, Enreig E, Menendez S, Rojo F, Noguera-Castells A, Bill A, Gaither L, Serrano L, Recalde-Percaz L, Moragas N, Alonso R, Ametller E, Rovira A, Lluch Hernández A, Albanell J, Gascon P, Bragado P. Clinical Cancer Research. 2020 Mar 15;26(6):1432-1448. doi: 10.1158/1078-0432.CCR-19-0353. PMID: 31699826